Charles Schwab’s Aprea Therapeutics APRE Stock Holding History

Charles Schwab’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,518	Closed	-$246K	–	3502
2021 Q2	$246K	Sell	2,518 -910	-27%	-$84.1K	﹤0.01%	3259
2021 Q1	$350K	Sell	3,428 -171	-5%	-$19.9K	﹤0.01%	3200
2020 Q4	$355K	Buy	3,599 +62	+2%	+$29.5K	﹤0.01%	3102
2020 Q3	$1.7M	Buy	3,537 +1,380	+64%	+$772K	﹤0.01%	2546
2020 Q2	$1.67M	Buy	2,157 +210	+11%	+$138K	﹤0.01%	2472
2020 Q1	$1.35M	Buy	1,947 +23	+1%	+$16.9K	﹤0.01%	2414
2019 Q4	$1.77M	Buy	+1,924	New	+$1.06M	﹤0.01%	2455

Other funds holding APRE

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Charles Schwab's APRE Position: Q3 2021 in Review

Charles Schwab sold out of Aprea Therapeutics (APRE) in Q3 2021, closing a stake of 2,518 shares — an estimated $246K sold.

Charles Schwab first reported a position in APRE in Q4 2019 and held it in 7 quarters. The position peaked at $1.77M in Q4 2019. 39 funds tracked by Wall St. Rank hold APRE as of Q3 2021.

Charles Schwab reported no remaining Aprea Therapeutics position as of Q3 2021 after selling out during the quarter.
Charles Schwab sold 2,518 Aprea Therapeutics shares in Q3 2021, an estimated $246K.
Charles Schwab first reported a position in Aprea Therapeutics in Q4 2019 and held it in 7 quarters.
Charles Schwab's Aprea Therapeutics position peaked at $1.77M in Q4 2019.
39 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2021.

Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.